Hair loss discussion focused on 2% Fluridil's peak efficacy at 3 months and 7% Fluridil group buy results, including shedding decrease, side effects, and regrowth.
A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
The potential hair regrowth benefits of ASC-J9, a synthetic modified version of curcumin that is said to be more effective than Minoxidil and Finasteride. Reports from users suggest good thickening and temple regrowth with topical use at 0.025% concentration.
GHK-Cu is being considered for hair growth, but users report mixed results. Some use it alongside other treatments like 5AR inhibitors, making it hard to determine its effectiveness.
A user's 7-month progress using 1 mg finasteride and topical minoxidil, with no side effects from the finasteride, achieving baby hairs on the hairline and other positive results. Other users have discussed different treatments such as microneedling and supplements, providing advice and encouragement to the poster.
The user experienced significant hair regrowth using 1 mg finasteride daily and 5% topical minoxidil once a day over seven months, with minor side effects like hypertrichosis. Consistency in treatment was emphasized, and the user reported improved hair density and texture without major side effects.
A user shared their 7-month progress on hair regrowth using a regimen of dutasteride, minoxidil, stemoxydine, microneedling, and keto shampoo. They noted significant improvement, particularly in vellus hair growth, and discussed the potential addition of RU58841, though they experienced side effects with it previously.
GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.
A 30-year-old male successfully improved hair density over 7 years using finasteride, minoxidil, microneedling, and recently added dutasteride. He experienced no side effects and noticed significant regrowth, especially after adding minoxidil and microneedling.
The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.
The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.
A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.
The user shared progress on hair regrowth after 7 months using Minoxidil 5% twice daily, Finasteride 1mg once daily, vitamin D3, and Neurobion injections. They encouraged others to persist with their treatments, noting visible improvements and expecting further gains.
The conversation is about the progress and development of a hair loss treatment called GT20029. People are discussing updates on its status and speculating on how long it will take to become available.
The user has been using finasteride for 7 months, along with dermarolling, Nizoral shampoo, vitamins, and minoxidil spray and oral minoxidil. They experienced variable hair shedding and improvement, and are concerned about the normalcy and future of their hair condition.
The user is seeing slow hair regrowth using Minoxidil, Finasteride, a derma roller, vitamins, and zinc. Some suggest switching to dutasteride or adding other treatments, but others doubt significant cosmetic improvement due to advanced hair loss.
The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.
The conversation discusses hair regrowth after 7 months of treatment, with the recent addition of tretinoin 0.05%. The treatment routine remained the same as before, except for this new addition.
The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.
The user has been on finasteride for 7 years and had a hair transplant, but is experiencing hair thinning and itchiness, particularly on one side, leading to concerns about male pattern baldness or other health issues. Despite having a full head of hair, the user is considering shaving it due to mental health struggles and is advised to consult a therapist and consider other treatments like minoxidil or dutasteride.
Significant hair regrowth was achieved using 1 mg Finasteride, 5% Minoxidil, and dermarolling, with a switch from a 0.5 mm to a 1 mm roller after two months. The user is happy with the results but is still considering a hair transplant for more density.
A 21-year-old used 1.25mg finasteride and minoxidil twice daily for hair regrowth, reducing finasteride to 5 times a week since September. He also started using Nizoral for dandruff, noticed an increased appetite, and experienced a temporary change in sex drive.
KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.
Hair transplants for NW7 individuals are challenging due to limited donor hair, often resulting in thin coverage unless body or beard hair is used. Treatments like minoxidil and finasteride are mentioned to support hair density and growth.
The user started using EssenGen 6-Plus, containing 6% minoxidil and 0.05% finasteride, along with 1% Nizoral shampoo, and reported noticeable hair growth in 7 weeks. They experienced some chest tightness but are monitoring it, and they are satisfied with the progress despite using a silicone-containing shampoo.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.